

1/21

Figure 1

Schematic representation of human tenascin-C and of the strategy followed for the generation of BC2-like antibodies





Figure 2


SDS-PAGE and Western Blot analysis of ST2485 antibody, in reducing (b, d) and non-reducing (a, c) conditions.



M: molecular weight standards

Figure 3

ST2485 antibody digestion with *Flavobacterium* Peptide-N-glycosidase enzyme (PNGase F).





- 1: Molecular weight marker
- 2: Non-digested ST2485
- 3: PNGaseF-digested ST2485

4/21

Figure 4


BC-2 and ST2485 antitenascin antibodies hydroxyapatite chromatography.



5/21

Figure 5

ST2485 antitenascin antibody Western Blot Analysis



1: Tenascin-C

2: Tn A₍₁₋₄₎-D Fragment

3: Tenascin EGF-like region recombinant fragment, containing the epitope recognized by BC-4 antibody.


MW: molecular weight standards

6/21


Figure 6

Competitive ELISA test between ST2485 and BC-2 for antigen binding.

a)



b)




7/21


Figure 7

Immunoreactivity of ST2485 antibody in comparison with BC-2, on tenascin C (a) and on Tn A₍₁₋₄₎-D fragment (b).

a)





b)



8/21

Figure 8


Immunoreactivity of ST2485 and BC-2 biotinylated and non-biotinylated antibodies, on tenascin-C (a) and on Tn A₍₁₋₄₎-D fragment (b).



9/21

Figure 9


Cross-reactivity of ST2485 antibody with murine tenascin.



10/21

Figure 10


Biotinylated ST2485 and BC-2 antibodies biodistribution study protocol in human tenascin-expressing tumor-implanted nude mice.



11/21


Figure 11

Biotinylated ST2485 and BC-2 biodistribution in human tenascin-expressing tumor-transplanted nude mice. The antibody amount is expressed as percent of the injected dose per tissue gram (% I.D./gr).



12/21



Figure 11a





13/21

Figure 12

Biotinylated ST2485 and BC-2 biodistribution in nude mice: tumor/non tumor ratio.



14/21


Figure 12a

15/21


Figure 13

Interference (a) and additivity (b) ST2485 and ST2146 antitenascin antibodies *in vitro* evaluation by ELISA test.

a) Interference




b) Additivity




16/21

Figure 14


Antibodies ST2485 and ST2146 tenascin binding *in vitro* additivity by BIACore



17/21


Figure 14a

c)



d)


18/21

Figure 15Schematic representation of *in vivo* additivity study in animal model

19/21

Figure 16

ST2485 e ST2146 antibodies additivity in animal model; tumor seat localization.



20/21

Figure 17

SEQID 1 sequence of ST2485 kappa light chain variable region (VL).

Signal peptide

ATGGATTTCAGTGCAGATTTCAGCTTCCTGCTAATCAGTGTTCAGTCATAATGTCCAGAGGACAAA
Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser Val Ile Met Ser Arg Gly Gln

TTGTTCTCTCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGGGGAGAAGGTCACAATGACTTGC
Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys

↓ N-glycosylation

CDR1
AGGGGCAACTCAAGTGTACGTTTCATGCACTGGTACCAGCAGAAGCCAGGATCCTCCCCCAAACC
Arg Ala Asn Ser Ser Val Arg Phe Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys

CDR2

CTGGATTATTCAGATCCAGCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGG
Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly

CDR3

GACCTCTTATCTGTCACAATCAGCAGAGTGGAGGCTGAAATGCTGCCACTTATTACTGCCAGC
Ser Gly Thr Ser Tyr Ser Val Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln

AGTGGAGTAGTAATTCACCCAGGACGTTCCGGTGGAGGCACCAAGGTGGAAATCAGACGGGCT
Gln Trp Ser Ser Asn Ser Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg Arg Ala

21 /21

Figure 18

SEQID 2 sequence of ST2485 gamma heavy chain variable region (VH)

Signal peptide

ATGGGATGGAGCTGGATCTTTCTCTTCCTCCTGTCAGGAACTGCAGGTGTCCACTCTGAGGTCCAGCTG
 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly Val His Ser Glu Val Gln Leu

CAACAGTCTGGACCTGAGCTGGTGAAGCCTGGAGCTTCAATGAAGATTTCCTGCAAGGCTTCTGG
 Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser

CDR1

TTACTCATTCACTTCCTGAGCCATGAACTGGGTGAAGCAGAGCCATGGAAAGAACCTTGAATGGA
 Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp

CDR2

TTGGACTTGGTCTGACAAATGGTGGTACTACCTACACCAGAAGTTCAAGGGCAAGGCCACA
 Ile Gly Leu Ile Asn Pro His Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr

TAACTGTAGACAAGTCATCCAACACAGCCTACATGGAGCTCCTCAGTCTGACATCTGAGGACTC
 Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Glu Leu Leu Ser Leu Thr Ser Glu Asp

CDR3

TGCAGTCTATTACTGTACAAGACCGGGGGTTACTACTGGTTCTTCGATGTCTGGGGCGCAGGGA
 Ser Ala Val Tyr Tyr Cys Thr Arg Pro Gly Gly Tyr Tyr Trp Phe Phe Asp Val Trp Gly Ala Gly

CCACGGTCACCGTCTCCTCA
 Thr Thr Val Thr Val Ser Ser